XOMA Corporation (XOMA)
Morgan Stanley Global Healthcare Conference
September 12, 2012 10:20 a.m. ET
Paul Rubin - Senior Vice President, Research and Development and Chief Medical Officer
Fred Kurland - Vice President-Finance and Chief Financial Officer
Yigal Nochomovitz - Morgan Stanley
Good morning everyone. Welcome to the XOMA session. My name is
I am one of the biotech analysts at Morgan Stanley. And so just a few orders of business before we get started. All relevant research disclosures from Morgan Stanley can be found on our website or on our publicly printed notes. And secondarily, this is meant to be an absolutely open question-and-answer session, so feel free to raise your hand and interrupt at any point. We have microphones circulating around the room.
So welcome, Paul Rubin, CMO of XOMA, and Fred Kurland, CFO. Welcome to the session. Maybe we could start off, Paul, just give us a little bit of an overview of XOMA. What are the key priorities of the company at this point? Just flush out the story for those that are not familiar with the company.
Sure. First thank you for having us here. XOMA is a discovery based biotechnology company that, not surprisingly people know, has been around for quite a while. But during the time it’s been around it’s developed I think a very proprietary method which to discover monoclonal antibodies. It probably has some of the best libraries in the world plus our ability to interrogate receptors, especially through use of allosteric modulation I think is very unique. And at the day we should be able to determine potential monoclonals that could be differentiated from many other companies in the world.